RHHBY

N/A

Roche Holding AG — PEG Ratio Analysis

—

PEG Ratio

Negative EPS growth — PEG not meaningful when earnings are declining

—

Growth Rate Source

Good Data Quality5-Year EPS CAGR

Current Price

$52.40

TTM EPS

$3.07

P/E Ratio

17.07

Growth Rate

-0.7%

5-Year EPS CAGR

Sector

Healthcare

Drug Manufacturers - General

Calculated

6/17/2026

10:36:33 AM

PEG Ratio Unavailable

Negative Growth — PEG not meaningful

Peer Comparison

Sample Size

6 peers

Industry Median PEG

1.20

25th Percentile

0.67

75th Percentile

1.53

Symbol	Company	PEG	P/E	Growth	vs RHHBY
GILD	Gilead Sciences, Inc.	0.12	17.3	149.5%	—
AZN	AstraZeneca PLC	0.67	26.9	40.2%	—
GSK	GSK plc	1.00	14.3	14.4%	—
NVS	Novartis AG	1.40	21.6	15.4%	—
MRK	Merck & Co., Inc.	1.53	32.4	21.2%	—

How to Interpret PEG Ratio

PEG < 1.0 — Potentially Undervalued. The stock may be priced below its earnings growth rate, suggesting a potential buying opportunity.

PEG 1.0–2.0 — Fairly Valued. The stock price is roughly in line with its earnings growth. A PEG of 1.0 is often considered "fair value."

PEG > 2.0 — Potentially Overvalued. The stock may be priced above what its earnings growth justifies.

Limitations:PEG ratios are less reliable for financial firms (earnings driven by interest margins), companies with negative/zero earnings growth, and hypergrowth companies (>100% growth) where the ratio may appear misleadingly low. Always use PEG alongside other valuation metrics.